Form 4: Forte Biosciences CEO Paul A. Wagner Reports Stock Transactions
SEC Form 4 Filing
Paul A. Wagner, CEO of Forte Biosciences, reports the vesting and disposal of restricted stock units and common stock.
Summary
- On July 1, 2024, Paul A. Wagner, CEO of Forte Biosciences, reported transactions involving the company's stock.
- Wagner vested 31,250 restricted stock units (RSUs) which converted into common stock.
- Simultaneously, Wagner disposed of 2,453 shares of common stock at a price of $0.546 per share.
- Following these transactions, Wagner directly owns 1,907,971 shares of Forte Biosciences common stock and 312,500 RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine insider transactions. The vesting of RSUs is a positive, but the sale of shares is a neutral event unless there are other factors to consider.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | Start date for quarterly vesting of RSUs. |
| 07/01/2024 | Date of stock transactions: vesting of RSUs and disposal of common stock. |
| 07/03/2024 | Date of signature for the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.